James Wf Catto


Affiliation: University of Sheffield
Country: UK


  1. McNeill R, Mason A, Hodson M, Catto J, Southgate J. Specificity of the Metallothionein-1 Response by Cadmium-Exposed Normal Human Urothelial Cells. Int J Mol Sci. 2019;20: pubmed publisher
  2. Peter S, Borkowska E, Drayton R, Rakhit C, Noon A, Chen W, et al. Identification of differentially expressed long noncoding RNAs in bladder cancer. Clin Cancer Res. 2014;20:5311-21 pubmed publisher
    ..We identify phenotype-specific expression and a potential mechanistic target to explain this observation. Further studies are required to validate lncRNAs as prognostic biomarkers in this disease. ..
  3. request reprint
    Catto J, Hartmann A, Stoehr R, Bolderson E, Rehman I, Rosario D, et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol. 2006;175:2323-30 pubmed
    ..These cells lead to subsequent tumor relapse and new methods are required to detect and eradicate them. ..
  4. Catto J, Abbod M, Linkens D, Larre S, Rosario D, Hamdy F. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Clin Cancer Res. 2009;15:3150-5 pubmed publisher
    ..It seems superior to other available predictive methods and could be used to identify patients who would potentially benefit from adjuvant chemotherapy. ..
  5. request reprint
    Catto J, Azzouzi A, Rehman I, Feeley K, Cross S, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 2005;23:2903-10 pubmed
    ..Methylation occurs commonly in urinary tract tumors, may affect carcinogenic mechanisms, and is a prognostic marker and a potential therapeutic target. ..
  6. request reprint
    Catto J, Yates D, Rehman I, Azzouzi A, Patterson J, Sibony M, et al. Behavior of urothelial carcinoma with respect to anatomical location. J Urol. 2007;177:1715-20 pubmed
    ..The current move to minimally invasive/nephron sparing techniques for urothelial carcinoma of the upper urinary tract appears safe. Care could be analogous to that for bladder urothelial carcinoma. ..
  7. Catto J, Abbod M, Wild P, Linkens D, Pilarsky C, Rehman I, et al. The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol. 2010;57:398-406 pubmed publisher
    ..We have identified a prognostic gene signature whose members reflect a variety of carcinogenic pathways that could identify progression in non-muscle-invasive BCa. ..
  8. Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol. 2016;70:1 pubmed publisher
    ..Editors of the major urological literature advocate the use of the recent Gleason Grade groupings when reporting analyses of prostate cancer. ..
  9. Autorino R, Porpiglia F, Dasgupta P, Rassweiler J, Catto J, Hampton L, et al. Precision surgery and genitourinary cancers. Eur J Surg Oncol. 2017;43:893-908 pubmed publisher

More Information


  1. Catto J, Alcaraz A, Bjartell A, de Vere White R, Evans C, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59:671-81 pubmed publisher
    ..Their expression is frequently altered in these tumours, and many are functionally implicated in their pathogenesis. They require evaluation to determine the translational role and therapeutic potential for this knowledge. ..
  2. Drayton R, Rehman I, Clarke R, Zhao Z, Pang K, Miah S, et al. Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. Cancer Epidemiol Biomarkers Prev. 2015;24:268-75 pubmed publisher
    ..This short RNA is stable ex vivo, suggesting a role as a robust biomarker. We identify cytoplasmic enrichment of this RNA and potential targeting of mRNAs implicated in prostate carcinogenesis. ..
  3. Panebianco V, Barchetti F, de Haas R, Pearson R, Kennish S, Giannarini G, et al. Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. Eur Urol Focus. 2016;2:113-121 pubmed publisher
    ..Multiparametric magnetic resonance imaging appears more accurate than current methods for local and nodal staging and monitoring tumor response to treatment, but requires further investigation. ..
  4. Noon A, Martinsen J, Catto J, Pukkala E. Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence. Eur Urol Focus. 2018;4:725-730 pubmed publisher
    ..These findings may be explained by confounding factors such as exposure to tobacco smoke; however, it could be that workers with these job titles are exposed to specific bladder carcinogens. ..
  5. Pang K, Groves R, Venugopal S, Noon A, Catto J. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol. 2017;: pubmed publisher
    ..Patients managed by these pathways have shorter length of stays, lower blood loss, and lower transfusion rates. Their adoption should be encouraged. ..
  6. Gordon P, Thomas F, Noon A, Rosario D, Catto J. Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. Eur Urol Focus. 2017;: pubmed publisher
    ..Guidelines advocate early re-resection for these cancers, although the benefits are unclear and the uniform need is questioned. Here, we compare the outcomes using a large single-center cohort...